Higher Risk of Hepatocellular Carcinoma in Hispanic Patients with Hepatitis C Cirrhosis and Metabolic Risk Factors

Overview

Journal Sci Rep

Specialty Science

Date 2018 May 10

PMID 29740031

Citations 7

Authors

Alina Wong

An Le

Mei-Hsuan Lee

Yu-Ju Lin

Pauline Nguyen

Sam Trinh

Hansen Dang

Mindie H Nguyen

Affiliations

Soon will be listed here.

Abstract

The effect of metabolic syndrome on chronic liver diseases other than non-alcoholic fatty liver disease has not been fully elucidated. Our goal was to evaluate if metabolic syndrome increased the risk of liver-related complications, specifically hepatocellular carcinoma (HCC) and decompensation, in cirrhotic chronic hepatitis C (CHC) patients. We conducted a retrospective cohort study of 3503 consecutive cirrhotic CHC patients seen at Stanford University from 1997-2015. HCC developed in 238 patients (8-year incidence 21%) and hepatic decompensation in 448 patients (8-year incidence 61%). The incidence of HCC and decompensation increased with Hispanic ethnicity, diabetes, and number of metabolic risk factors. Multivariate Cox regression analysis demonstrated that, independent of HCV therapy and cure and other background risks, Hispanic ethnicity with ≥2 metabolic risk factors significantly increased the risk of HCC and hepatic decompensation. There was no interaction between Hispanic ethnicity and metabolic risk factors. All in all, metabolic risk factors significantly increase the risk of liver-related complications in cirrhotic CHC patients, especially HCC among Hispanics. As the prevalence of metabolic syndrome increases globally, targeted health interventions are needed to help curb the effects of metabolic syndrome in CHC patients.

Citing Articles

Associations of Race and Ethnicity with Hepatocellular Carcinoma, Decompensation, and Mortality in US Veterans with Cirrhosis.

VoPham T, Cravero A, Feld L, Green P, Feng Z, Berry K Cancer Epidemiol Biomarkers Prev. 2023; 32(8):1069-1078.

PMID: 37255388 PMC: 10390887. DOI: 10.1158/1055-9965.EPI-22-1291.

Cannabis Use Is Inversely Associated with Metabolic Disorders in Hepatitis C-Infected Patients (ANRS CO22 Hepather Cohort).

Barre T, Bourliere M, Ramier C, Carrat F, Di Beo V, Protopopescu C J Clin Med. 2022; 11(20).

PMID: 36294456 PMC: 9605108. DOI: 10.3390/jcm11206135.

Autoantibody against Tumor-Associated Antigens as Diagnostic Biomarkers in Hispanic Patients with Hepatocellular Carcinoma.

Ma Y, Qiu C, Wang B, Zhang X, Wang X, Aguilera R Cells. 2022; 11(20).

PMID: 36291095 PMC: 9600682. DOI: 10.3390/cells11203227.

Short-Chain Fatty Acids: A Soldier Fighting Against Inflammation and Protecting From Tumorigenesis in People With Diabetes.

Yang Q, Ouyang J, Sun F, Yang J Front Immunol. 2020; 11:590685.

PMID: 33363537 PMC: 7752775. DOI: 10.3389/fimmu.2020.590685.

Interleukin-6-174G/C polymorphism is associated with a decreased risk of type 2 diabetes in patients with chronic hepatitis C virus.

da Silva C, Vieira D, de Melo L, Chagas A, Gomes A, de Faria Jr C World J Hepatol. 2020; 12(4):137-148.

PMID: 32685106 PMC: 7336292. DOI: 10.4254/wjh.v12.i4.137.

References

Bruix J, Sherman M . Management of hepatocellular carcinoma: an update. Hepatology. 2011; 53(3):1020-2. PMC: 3084991. DOI: 10.1002/hep.24199. View

Stepanova M, Rafiq N, Younossi Z . Components of metabolic syndrome are independent predictors of mortality in patients with chronic liver disease: a population-based study. Gut. 2010; 59(10):1410-5. DOI: 10.1136/gut.2010.213553. View

Chen Y, Wang X, Wang J, Yan Z, Luo J . Excess body weight and the risk of primary liver cancer: an updated meta-analysis of prospective studies. Eur J Cancer. 2012; 48(14):2137-45. DOI: 10.1016/j.ejca.2012.02.063. View

Yang J, Mohamed H, Cvinar J, Gores G, Roberts L, Kim W . Diabetes Mellitus Heightens the Risk of Hepatocellular Carcinoma Except in Patients With Hepatitis C Cirrhosis. Am J Gastroenterol. 2016; 111(11):1573-1580. PMC: 6040826. DOI: 10.1038/ajg.2016.330. View

Svegliati-Baroni G, Ridolfi F, Di Sario A, Casini A, Marucci L, Gaggiotti G . Insulin and insulin-like growth factor-1 stimulate proliferation and type I collagen accumulation by human hepatic stellate cells: differential effects on signal transduction pathways. Hepatology. 1999; 29(6):1743-51. DOI: 10.1002/hep.510290632. View

El-Serag H, Kramer J, Duan Z, Kanwal F . Racial differences in the progression to cirrhosis and hepatocellular carcinoma in HCV-infected veterans. Am J Gastroenterol. 2014; 109(9):1427-35. DOI: 10.1038/ajg.2014.214. View

Thompson A, Patel K, Chuang W, Lawitz E, Rodriguez-Torres M, Rustgi V . Viral clearance is associated with improved insulin resistance in genotype 1 chronic hepatitis C but not genotype 2/3. Gut. 2011; 61(1):128-34. PMC: 3766841. DOI: 10.1136/gut.2010.236158. View

Mehta S, Brancati F, Sulkowski M, Strathdee S, Szklo M, Thomas D . Prevalence of type 2 diabetes mellitus among persons with hepatitis C virus infection in the United States. Hepatology. 2001; 33(6):1554. DOI: 10.1053/jhep.2001.0103306le01. View

. Global prevalence and genotype distribution of hepatitis C virus infection in 2015: a modelling study. Lancet Gastroenterol Hepatol. 2017; 2(3):161-176. DOI: 10.1016/S2468-1253(16)30181-9. View

10.

Huang P . A comprehensive definition for metabolic syndrome. Dis Model Mech. 2009; 2(5-6):231-7. PMC: 2675814. DOI: 10.1242/dmm.001180. View

11.

Kasmari A, Welch A, Liu G, Leslie D, McGarrity T, Riley T . Independent of Cirrhosis, Hepatocellular Carcinoma Risk Is Increased with Diabetes and Metabolic Syndrome. Am J Med. 2017; 130(6):746.e1-746.e7. DOI: 10.1016/j.amjmed.2016.12.029. View

12.

Wong R, Gish R . Metabolic Manifestations and Complications Associated With Chronic Hepatitis C Virus Infection. Gastroenterol Hepatol (N Y). 2016; 12(5):293-9. PMC: 4973560. View

13.

Veldt B, Chen W, Heathcote E, Wedemeyer H, Reichen J, Hofmann W . Increased risk of hepatocellular carcinoma among patients with hepatitis C cirrhosis and diabetes mellitus. Hepatology. 2008; 47(6):1856-62. DOI: 10.1002/hep.22251. View

14.

Adinolfi L, Gambardella M, Andreana A, Tripodi M, Utili R, Ruggiero G . Steatosis accelerates the progression of liver damage of chronic hepatitis C patients and correlates with specific HCV genotype and visceral obesity. Hepatology. 2001; 33(6):1358-64. DOI: 10.1053/jhep.2001.24432. View

15.

Bozeman S, Hoaglin D, Burton T, Pashos C, Ben-Joseph R, Hollenbeak C . Predicting waist circumference from body mass index. BMC Med Res Methodol. 2012; 12:115. PMC: 3441760. DOI: 10.1186/1471-2288-12-115. View

16.

Arase Y, Kobayashi M, Suzuki F, Suzuki Y, Kawamura Y, Akuta N . Effect of type 2 diabetes on risk for malignancies includes hepatocellular carcinoma in chronic hepatitis C. Hepatology. 2012; 57(3):964-73. DOI: 10.1002/hep.26087. View

17.

Waris G, Felmlee D, Negro F, Siddiqui A . Hepatitis C virus induces proteolytic cleavage of sterol regulatory element binding proteins and stimulates their phosphorylation via oxidative stress. J Virol. 2007; 81(15):8122-30. PMC: 1951320. DOI: 10.1128/JVI.00125-07. View

18.

Mozumdar A, Liguori G . Persistent increase of prevalence of metabolic syndrome among U.S. adults: NHANES III to NHANES 1999-2006. Diabetes Care. 2010; 34(1):216-9. PMC: 3005489. DOI: 10.2337/dc10-0879. View

19.

Aguilar M, Bhuket T, Torres S, Liu B, Wong R . Prevalence of the metabolic syndrome in the United States, 2003-2012. JAMA. 2015; 313(19):1973-4. DOI: 10.1001/jama.2015.4260. View

20.

Younossi Z, Koenig A, Abdelatif D, Fazel Y, Henry L, Wymer M . Global epidemiology of nonalcoholic fatty liver disease-Meta-analytic assessment of prevalence, incidence, and outcomes. Hepatology. 2015; 64(1):73-84. DOI: 10.1002/hep.28431. View